

●► **Alchemab** *(Collaboration)*

Alchemab licensed its ATLX-1282 program to Eli Lilly, with Alchemab lead early Phase 1 trials and Lilly will handle further development and commercialization

●► **GRIN Therapeutics** *(EMA, CHMP Opinion, Orphan designation)*

EMA CHMP granted a positive orphan designation for GRIN Therapeutics radiprodil, following its recent PRIME status from EMA and Breakthrough Therapy and Orphan Drug designations from the FDA

●► **GeneFab** *(Collaboration, Clinical Manufacturing, Auto immune disease)*

GeneFab partnered with RegCell to support the US clinical manufacturing of RegCell's Treg therapies for autoimmune diseases

●► **Genezen** *(Collaboration, CAR-T therapy)*

Genezen and Optieum Biotechnologies form strategic partnership to advance cGMP manufacturing of OPTF01, a next-generation CAR-T therapy targeting glioblastoma

●► **Mersana** *(Layoff, R&D)*

Mersana restructures to extend runway, prioritize Emi-Le in breast cancer; 55% workforce cut is expected by Q3 2025

●► **ProBioGen** *(Collaboration, Cell line, Biosimilar)*

ProBioGen and Polpharma Biologics partner for cell line development to advance biosimilar pipeline, supporting the expansion of their growing

